# Also in the Article

Dose-response curve analysis
This protocol is extracted from research article:
Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors
J Enzyme Inhib Med Chem, Jan 12, 2021;

Procedure

SARS-CoV-2 3CLpro was incubated with drugs at 0–100 µM for an hour at 37 °C. Then, 1.25 µM IQF peptide substrate was added to the mixture to a final volume of 100 µL and incubated at 37 °C for another three hours, prior to detection. With the same parameters applied in protease activity assays, the RFU readouts obtained from the SPARK® multimode microplate reader (TECAN, Switzerland) were normalised to the negative control (vehicle only) in each assay plate. After drug treatment at a concentration between 0–100 µM, points of relative protease activity were fitted to a normalised dose-response model in GraphPad Prism 7.03 for IC50 characterisation, where $Y=Bottom+Top−Bottom1+10(LogIC50−X)·HillSlope$ .

Note: The content above has been extracted from a research article, so it may not display correctly.

# Also in the Article

Q&A
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.